Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/211235
COMPARTIR / EXPORTAR:
logo share SHARE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Campo DC Valor Lengua/Idioma
dc.contributor.authorGonzález-Martín, Alicia-
dc.contributor.authorAndrabi, Raiees-
dc.contributor.authorFuller, Roberta P.-
dc.contributor.authorMurrell, Ben-
dc.contributor.authorMcCoy, Laura E.-
dc.contributor.authorPorter, Katelyn-
dc.contributor.authorHuang, Deli-
dc.contributor.authorLi, Wenjuan-
dc.contributor.authorSok, Devin-
dc.contributor.authorLe, Khoa-
dc.contributor.authorBriney, Bryan-
dc.contributor.authorChateau, Morgan-
dc.contributor.authorRogers, Geoffrey-
dc.contributor.authorHangartner, Lars-
dc.contributor.authorFeeney, Ann J.-
dc.contributor.authorNemazee, David-
dc.contributor.authorCannon, Paula-
dc.contributor.authorBurton, Dennis R.-
dc.contributor.authorVoss, James E.-
dc.date.accessioned2020-05-13T08:35:06Z-
dc.date.available2020-05-13T08:35:06Z-
dc.date.issued2019-05-09-
dc.identifier.citationAnnual Meeting of the American Association of Immunologists (2019)-
dc.identifier.urihttp://hdl.handle.net/10261/211235-
dc.descriptionTrabajo presentado en el Annual Meeting of the American Association of Immunologists, celebrado en San Diego, California (Estados Unidos) del 9 al 13 de mayo de 2019.-
dc.description.abstractHIV infection is a global health concern affecting roughly 37 million people and still no effective vaccine is available for prevention. While rare, HIV broadly neutralizing antibodies (bnAbs) have been isolated from patients. These antibodies have been shown to be protective in animal models if present at the time of challenge in passive transfer experiments. Thus, elicitation of HIV bnAbs is a central goal for vaccine design. These antibodies, however, contain rare features not present in the naïve human antibody repertoire. We have developed a universal genome editing strategy to introduce novel paratopes into the human repertoire. We used CRISPR-Cas9 in a homology directed repair strategy, to replace the heavy chain (HC) variable region in B cell lines and human primary B cells with that from an HIV broadly neutralizing antibody, PG9. The modified locus expresses PG9 HC which pairs with native light chains resulting in the cell surface expression of HIV specific BCRs. The engineered B cells are subject to class switch recombination and somatic hypermutation to generate HIV-specific BCRs with improved neutralizing breath and potency.-
dc.languageeng-
dc.rightsclosedAccess-
dc.titleReprogramming the antigen specificity of B cells using genome-editing technologies-
dc.typecomunicación de congreso-
dc.date.updated2020-05-13T08:35:06Z-
dc.relation.csic-
dc.type.coarhttp://purl.org/coar/resource_type/c_5794es_ES
item.openairetypecomunicación de congreso-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
Aparece en las colecciones: (IIBM) Comunicaciones congresos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Show simple item record

CORE Recommender

Page view(s)

145
checked on 28-mar-2024

Download(s)

18
checked on 28-mar-2024

Google ScholarTM

Check


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.